Hematopoietic Development and Malignancy
Program Leaders: Daniel Link, MD, PhD, and Peter Westervelt, MD, PhD
The Hematopoietic Development and Malignancy Program (HDMP) includes 29 Washington University faculty members from four departments. The long-term goals of the HDMP are to elucidate basic mechanisms regulating normal and malignant hematopoiesis and use this information to develop strategies for the prevention, diagnosis, prognostic stratification and treatment of hematopoietic malignancies. We have identified areas of institutional strength and developed the following specific translational goals:
- To leverage local expertise in cancer genomics to identify key genetic and epigenetic alterations in hematopoietic malignancies and develop their translational potential
- To Develop fundamental discoveries in immunology into novel immunotherapies for hematopoietic malignancies
- To translate fundamental discoveries in stem cell biology into novel strategies to treat hematopoietic malignancies and/or improve stem cell transplantation
- To expand translational research in multiple myeloma and lymphoma
Groups in leukemia, lymphoma & myeloma, myelodysplastic syndrome and transplantation biology have been established to develop, review, prioritize and conduct translational research. The HDMP fosters collaborative translational research and provides training of junior investigators through research seminars, journal clubs, work-in-progress meetings and the annual HDMP retreat.